Skip to main content
Category

News

Robert H Smith school

‘Business of Life Sciences and Healthcare for Leaders’ Forthcoming from UMD Smith Executive Education

By News, News Archive

Robert H Smith schoolCOLLEGE PARK, Md.March 26, 2025 /PRNewswire/ — Registration is open for “Business of Life Sciences and Healthcare for Leaders” (B-LSHC) — an immersive five-day program focused on leadership development and honing critical-thinking and problem-solving skills in medical product development presented by Smith Executive Education at the University of Maryland’s Robert H. Smith School of Business.

The in-person program takes place June 23-27, 2025, at Van Munching Hall on UMD’s College Park campus and is designed for mid-to-advanced career professionals in the LSHC ecosystem including pharmaceutical, biotech and medical device industries; health policy; patient advocacy; regulators; investors; and leaders across medical and regulatory fields.

Program sessions will begin at 8:30 a.m. each day “and end with a luminary keynote speaker who will inspire and challenge participants to think outside the box toward the goals of creating innovative solutions for some of our most challenging problems in the LSHC ecosystem,” says Wendy Sanhai, PhD, professor of the practice in management and organization for the Smith School and one of the workshop’s organizers. 

Read More
George Mason

RAPPNEWS: George Mason University celebrates $107M life sciences and engineering building in Manassas

By News, News Archive

George MasonEmily Seymour | InsideNoVa Mar 28, 2025 – George Mason University held the grand opening of its new life sciences and engineering building in Manassas on Thursday, celebrating the addition to its Science and Technology Campus.

The $107 million project supports the university’s growing need for specialized instructional labs, classrooms and support spaces for students, officials said. The building has classrooms and more than 30 different lab spaces for teaching, design and fabrication, offering hands-on learning for students across a number of disciplines.

University leaders celebrated the opening Thursday, joined by local leaders, including Virginia Del. Luke Torian, Del. Ian Lovejoy, Del. Briana Sewell, state Sen. Danica Roem and several members of the Prince William Board of County Supervisors.

Read More
Seal of Prince William County Virginia

BISNOW: Fueled By A Strong Pipeline, Prince William County Is A Thriving Alternative For Emerging Life Sciences Innovators

By News, News Archive

Seal of Prince William County VirginiaMarch 25, 2025 – John Knowles, Studio B Writer – The BioCapital Region, which includes Washington, D.C., Maryland and Virginia, is one of the top life sciences clusters in the United States.

Prince William County has rapidly emerged as a key player in Northern Virginia’s life sciences sector. The Prince William County Department of Economic Development and Tourism, or PWCDEDT, has been focused on diversifying the economy and leveraging assets like George Mason University’s Science and Technology Campus to attract innovative companies to the region.

PWCDEDT Deputy Director Trevor Johnson said that the county’s life sciences growth can be traced back to its abundant rural land, offering a rare opportunity for expansion in the Greater Washington area.

Read More
Eluta

Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro™

By News, News Archive

ElutaSILVER SPRING, Md., March 27, 2025 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, announced that it has entered into an agreement with Advantus Health Partners (“Advantus”), to provide access of Elutia’s EluPro™ Antibiotic Eluting BioEnvelope to Advantus’ core group purchasing organizations (GPO) solutions portfolio.

“Teaming up with Advantus is another major step forward in meeting the strong customer demand for EluPro,” said Dr. Kimberly Mulligan, GM and VP of Elutia’s Cardiovascular Division. “Our pilot launch of EluPro has exceeded our expectations as physicians recognize the unique value that this antibiotic envelope brings in preventing infection for patients that use a cardiac implantable electronic device. Broadening our GPO coverage with Advantus allows us to benefit from their sustainable contracting solutions, making EluPro more widely available to physicians nationwide.”

Read More
corvista logo79

CorVista Health Presents New Data on Non-Invasive Point of Care Testing for Pulmonary Capillary Wedge Pressure (PCWP) Elevation Using Machine Learning

By News, News Archive

corvista logo79BETHESDA, Md., March 31, 2025 (GLOBE NEWSWIRE) — CorVista Health today announced a poster presentation showcasing preliminary results of its machine learning-based algorithm for non-invasively estimating pulmonary capillary wedge pressure (PCWP) elevation – a key indicator of heart failure with preserved ejection fraction. The poster titled ‘Point-of-Care Testing for Pulmonary Capillary Wedge Pressure Elevation Using Machine Learning on Non-invasive Signals’ was presented at the American College of Cardiology’s Annual Scientific Session (ACC.25) in Chicago on March 30, 2025.

Currently, PCWP is measured through an invasive right heart catheterization (iRHC) procedure that requires a cardiologist, pulmonologist or intensivist. The CorVista capture device collects non-invasive signals for 3.5 minutes in patients at rest, which could potentially provide an alternative to iRHC in certain patient populations. The data demonstrate how machine learning signal analysis of a symptomatic population may provide a robust, non-invasive alternative to measuring PCWP elevation, potentially making early detection of HFpEF and PH subtypes more accessible.

Read More
4MLK

CoStar: A life sciences field of dreams takes shape with the opening of 4MLK

By News, News Archive

4MLKBy Dan Beyers, Katelyn Keiser – CoStar News – March 26, 2025 – If there is a field of dreams in Baltimore these days, it might be 4MLK, the gleaming new eight-story, 250,000-square-foot lab and office building that stands at the gateway of the University of Maryland’s life science and technology center, BioPark.

When it is fully leased, 4MLK hopes to house the largest cluster of bioscience companies in the greater Baltimore region, bringing 1,000 jobs to the city and doubling the size of the workforce now employed by nearly three dozen companies at the center. It’s an ambition that earned the project a 2025 CoStar Impact Award as judged by real estate professionals in the market.

Read More
Solaxa

Solaxa Announces Phase 3 Clinical Trial for Spinocerebellar Ataxia Type 27B

By News, News Archive

SolaxaBethesda, MD — March 28, 2025 – Solaxa Inc., a biopharmaceutical public benefit corporation focused on rare neurological conditions, has announced plans to conduct a registrational clinical trial evaluating its investigational therapy, SLX-100, for spinocerebellar ataxia type 27B (SCA27B).

This pivotal-powered study will be funded in part by a $7.3 million dollar grant awarded to Dr. Susan Perlman, MD, at the University of California, Los Angeles by the Congressionally Directed Medical Research Program. Solaxa will serve as the regulatory sponsor of the trial and partner with leading ataxia centers of excellence. Additional clinical trial sites will be announced later this year.

There are currently no FDA approved therapies for SCA27B, a rare hereditary ataxia. “We are thrilled to move one step closer to impacting the lives of people living with SCA27B,” said Christian Walker, CEO & Founder of Solaxa.

Read More
Secretome

Secretome Therapeutics Begins First Trial of STM-01 for Heart Failure

By News, News Archive

SecretomePLANO, Texas & BALTIMORE–(BUSINESS WIRE)–Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced dosing of the first patient in its Phase 1 clinical trial evaluating STM-01 as a treatment for heart failure with preserved ejection fraction (HFpEF).

This is the first-ever clinical study of an allogeneic, off-the-shelf stem cell therapy in HFpEF, a leading cause of hospitalization, morbidity, and mortality worldwide. An estimated 6.7 million adults in the U.S. are affected by heart failure, with HFpEF comprising at least half of these cases.

Read More
ATCC

ATCC Appoints Dr. Ruth Cheng as New President and Chief Executive Officer

By News, News Archive

ATCCRuth R. Cheng, PhD, succeeds Raymond H. Cypess, DVM, PhD, who will remain on the Board of Directors as chairman

Dr. Cheng is an experienced global executive leader in life sciences innovation and business strategy, with a strong background in biology and biomedical engineering

Manassas, VA, United States – January 17, 2025 – ATCC, the world’s premier biological materials management and standards organization, today announced the appointment of Ruth Cheng, PhD, as president and chief executive officer. Dr. Cheng, who has been with ATCC for five years and most recently served as senior vice president and general manager, Research and Industrial Solutions, succeeds Raymond H. Cypess, DVM, PhD, who will remain on the Board of Directors as chairman.

“ATCC has grown into the world’s largest and most diverse biological resource center,” said Dr. Cheng. “It is my goal to continue building upon this solid foundation at ATCC to expand the next generation of scientific innovation and digital biological discovery. I am grateful to Dr. Cypess and the Board of Directors for their confidence in me to lead this organization. My scientific training and business roles have prepared me well for this position and I am extremely optimistic about the future of ATCC.”

“Dr. Cheng’s vision of where we could go, how we could get there, and what steps to take aligned with that of Dr. Cypess. It became obvious to us that she was the best choice, especially with her track record of accomplishments,” said ATCC board member, Steven G. Kaminsky. “After an extensive search process for a new CEO, Dr. Cheng rose to the top and the Board unanimously appointed Dr. Cheng, who understood the culture and mission of ATCC and demonstrated the clarity of thought as to the company’s future.”

During her tenure at ATCC, Dr. Cheng has contributed to the continuous transformation of ATCC’s culture and strategy through internal innovation and new external partnerships globally. Her leadership has positioned the company into areas important to ATCC’s future including bioinformatics and biological reference data. Additionally, she has expanded the number and diversity of its scientific strategic partnerships.

“Dr. Cheng understands the importance of the company’s hybrid approach to being a financially self-sustaining non-profit organization,” said Dr. Cypess. “This business model reinforces our ability to remain committed to improving global public health, advancing science, and ensuring the safety and security of the United States. Dr. Cheng, as well as my fellow Board members and I, are here to serve the company, its employees, and stakeholders. As I pass the baton to Dr. Cheng, I know that ATCC is in good hands and will continue to make sound science possible for researchers around the world.”

Before joining ATCC, Dr. Cheng served as vice president of Global Strategy at AgNovos Healthcare, where she led multiple departments and strategic initiatives to expand the company’s portfolio and market access. She was director of Innovation and Strategy for the Advanced Surgical Devices Division of Smith+Nephew, where she oversaw strategic planning and was responsible for portfolio expansion through product development and corporate venturing. And earlier in her career, Dr. Cheng worked at Boston Scientific as manager of Corporate Research and Research Fellow and Strategic Partnerships. She brings extensive business leadership experience across global markets including Europe and the Asia-Pacific region.

Dr. Cheng received her master’s of science and doctorate degrees in biomedical engineering from the University of Michigan after earning a Bachelor of Arts in biological sciences from Cornell University. She holds executive certificates in Strategy and Innovation from MIT Sloan School of Management, and Private Equity and Venture Capital from Harvard Business School. Dr. Cheng has authored numerous scientific publications and has more than a dozen patents. She also is an invited lecturer at congresses and universities on medical technology innovation.

“It has been my privilege to work alongside such a talented team at ATCC whose unique skills and expertise have made us the most trusted, credible biorepository in the world,” said Dr. Cheng. “The people here do incredible work, which enables others to make incredible discoveries.”

About ATCC
ATCC is a premier global biological materials and information resource and standards organization and the leading developer and supplier of authenticated cell lines, microorganisms, and associated data for academia, industry, and government. With a history of scientific contributions spanning more than a century, ATCC offers an unmatched combination of being the world’s largest and most diverse collection of biological reference materials and data, and is a mission-driven, trusted partner that supports and encourages scientific collaboration. ATCC products, services, partnerships, and people provide the global scientific community with credible, advanced model systems to support complex research and innovations in basic science, drug discovery, translational medicine, and public health. ATCC is a 501(c)3 nonprofit organization headquartered in Manassas, Virginia, with research and technology centers of excellence in Gaithersburg and Germantown, Maryland.

Contact: Samantha Paro, senior manager, Corporate Communications & Public Affairs, ATCC, pr@atcc.org

NanoQT

Maryland Commerce: Japanese quantum company lays down roots in Maryland

By News, News Archive

NanoQTNanoQT, a Tokyo-based quantum computing company, recently announced its expansion into Maryland, with the intent to strengthen the company’s research and development capabilities and commercialization in the U.S.

The move follows the company’s participation in Maryland’s Global Gateway program, which incentivizes foreign companies to “soft land” in the U.S., offering affordable office spaces at Maryland incubators as well as access to advisors and other resources. As a Global Gateway participant, NanoQT took up residency at the Quantum Startup Foundry incubator on the University of Maryland campus, where the company will maintain its presence.

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.